top of page

Tour of Scotland: Outrun Therapeutics is aiming to create a new category of therapeutics by stabilizing proteins via drugging E3 ligases

7 days ago

CEO Carolyn Porter describes the beginning of the company, which spun out of University of Dundee's MRC Protein Phosphorylation and Ubiquitylation Unit (PPU). The first goal is to go after hard to treat solid tumors.

Recent Posts

The co-founders of Vevo Therapeutics describe the Arc Virtual Cell Atlas, a large single cell atlas made publicly available with Arc Institute that now includes Vevo's Tahoe-100M database

The co-founders of Vevo Therapeutics describe the Arc Virtual Cell Atlas, a large single cell atlas made publicly available with Arc Institute that now includes Vevo's Tahoe-100M database

Bonum Therapeutics aims to lower the toxicity of medicines such as cytokines by regulating them via a unique sensor domain that is designed to activate a therapeutic at its target

Bonum Therapeutics aims to lower the toxicity of medicines such as cytokines by regulating them via a unique sensor domain that is designed to activate a therapeutic at its target

Tour of Scotland: Glasgow based EnteroBiotix is developing microbiome based treatments using a 'full ecosystem' of strains you would expect to see in a healthy microbiome

Tour of Scotland: Glasgow based EnteroBiotix is developing microbiome based treatments using a 'full ecosystem' of strains you would expect to see in a healthy microbiome

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

Visit Savills' Life Sciences Overview

bottom of page